Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5826086 | Current Opinion in Pharmacology | 2014 | 4 Pages |
Abstract
Migraine continues to be the most common of the debilitating headaches. Existing acute headache treatments are not always satisfactory, and current research is focussed on targeting neuroinflammatory pathways with drugs that are devoid of vascular action. Current prophylactic drugs are largely centred around antihypertensive, anticonvulsant and antidepressant drugs, although not all drugs of all sub-classes in these categories are effective. Selective agents which target the neuroinflammatory process including targets such as calcitonin gene related peptide, and PANNEXIN 1 may have clinical utility.
Related Topics
Life Sciences
Neuroscience
Cellular and Molecular Neuroscience
Authors
Paul Edward Rolan,